BeyondSpring Inc.

NasdaqCM BYSI

BeyondSpring Inc. Current Liabilities for the quarter ending June 30, 2024

BeyondSpring Inc. Current Liabilities is NA for the quarter ending June 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

BeyondSpring Inc. Current Liabilities for the quarter ending June 30, 2021 was USD 16.57 M, a 46.57% change year over year.
BeyondSpring Inc. Current Liabilities for the quarter ending June 30, 2020 was USD 11.31 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqCM: BYSI

BeyondSpring Inc.

CEO	Dr. Lan Huang Ph.D.
IPO Date	March 9, 2017
Location	United States
Headquarters	28 Liberty Street
Employees	36
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals Vaccines

Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Key trends

Past 5 years